Intech Investment Management LLC Has $3.22 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Intech Investment Management LLC boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 147.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 56,305 shares of the biopharmaceutical company’s stock after buying an additional 33,542 shares during the quarter. Intech Investment Management LLC’s holdings in Halozyme Therapeutics were worth $3,223,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of HALO. Advisors Asset Management Inc. lifted its stake in shares of Halozyme Therapeutics by 5.8% during the third quarter. Advisors Asset Management Inc. now owns 39,646 shares of the biopharmaceutical company’s stock valued at $2,269,000 after acquiring an additional 2,174 shares during the period. Segall Bryant & Hamill LLC raised its holdings in Halozyme Therapeutics by 16.3% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock worth $20,330,000 after purchasing an additional 49,856 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in Halozyme Therapeutics during the 3rd quarter valued at about $1,899,000. Quest Partners LLC boosted its stake in shares of Halozyme Therapeutics by 1,386.0% in the 3rd quarter. Quest Partners LLC now owns 9,793 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 9,134 shares during the last quarter. Finally, TrinityPoint Wealth LLC acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $214,000. 97.79% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price objective for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Morgan Stanley increased their target price on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Piper Sandler raised their target price on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. Finally, Benchmark reaffirmed a “buy” rating and issued a $60.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $61.11.

Halozyme Therapeutics Stock Up 7.2 %

Shares of Halozyme Therapeutics stock opened at $49.00 on Friday. Halozyme Therapeutics, Inc. has a 1 year low of $33.15 and a 1 year high of $65.53. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The company has a market capitalization of $6.23 billion, a P/E ratio of 16.23, a price-to-earnings-growth ratio of 0.42 and a beta of 1.29. The business has a 50-day moving average of $54.58 and a two-hundred day moving average of $53.48.

Insider Buying and Selling

In related news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total transaction of $532,600.00. Following the sale, the senior vice president now directly owns 173,756 shares in the company, valued at $9,254,244.56. This trade represents a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last three months, insiders sold 60,000 shares of company stock valued at $3,425,000. 2.40% of the stock is owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.